21 Proteomics, Genomics & Microarrays Rapid membrane protein synthesis accelerates drug discovery


Nuclera has enhanced its eProtein Discovery™ system with a dedicated membrane protein production workfl ow, enabling researchers to express and purify functional membrane proteins in just 48 hours. This advancement opens the door to faster discovery of drug targets and improved structural biology pipelines by tackling one of the most complex areas of protein science.


Membrane proteins are critical to cellular function and represent targets for over 60% of FDA-approved drugs. Yet their production remains notoriously diffi cult due to their hydrophobic nature and structural complexity. Nuclera’s expanded eProtein Discovery capabilities address this bottleneck by integrating cell-free expression, digital microfl uidics, and tailored additive screening to produce soluble, correctly folded membrane proteins ready for downstream applications such as cryo-EM.


To demonstrate this capability, Nuclera synthesised two well-characterised membrane proteins: the transporter MsbA and the integral membrane protein ZMPSTE24. Within 24 hours, the platform screened multiple conditions using nanodiscs, detergents, and lipid additives to identify optimal solubility and stability conditions. Both proteins were then scaled up to functional quantities within 48 hours, with high yield and quality suitable for structural and functional analyses.


Dr Toby Ost, SVP of Product Development at Nuclera, commented: “Membrane proteins have traditionally been diffi cult to work with, often yielding misfolded or inactive products. With this update, eProtein Discovery empowers researchers to overcome those barriers and accelerate their experimental timelines.”


Dr Konstantinos Beis, Reader in Membrane Protein Structural Biology at Imperial College London, added: “We evaluated membrane proteins produced with the eProtein Discovery system through Imperial Consultants. The results look promising - this could be a valuable tool for the community.”


The membrane protein workfl ow is available immediately to all current eProtein Discovery users via a software update. More information online: ilmt.co/PL/EDqw


64856pr@reply-direct.com Multiomic sequencing assays advance methylation studies


EpiCypher, a leader in epigenomic technologies, has introduced two innovative DNA methylation sequencing assays - CUTANA® meCUT&RUN and Multiomic CUT&RUN - that offer scalable, high- resolution insights into gene regulation to accelerate drug discovery.


Building on their established CUT&RUN platform, which enables precise chromatin profi ling from minimal input and reduces sequencing expenses, these new assays extend its capabilities to DNA methylation analysis. DNA methylation is a key epigenetic modifi cation that controls gene expression and cellular identity, but traditional bisulphite sequencing methods often suffer from DNA damage, high costs, and large sample requirements, limiting their broader use.


The CUTANA® meCUT&RUN assay uses a novel methyl-DNA binding fusion protein to specifi cally enrich 5-methylcytosine (5mC) with base-pair precision. This method detects over 80% of methylated CpGs compared to whole-genome techniques while requiring more than 20 times less sequencing, offering a highly sensitive and affordable alternative for methylation mapping.


Expanding on this, the Multiomic CUT&RUN assay enables simultaneous profi ling of DNA methylation alongside chromatin features such as histone modifi cations or DNA-binding proteins in a single experiment. This dual profi ling reveals complex epigenetic interactions, providing valuable data for basic research and translational drug development.


Both assays are compatible with low cell inputs, including cell lines, primary cells, and patient-derived samples, and offer streamlined workfl ows suited for diverse research and drug discovery applications.


More information online: ilmt.co/PL/wYED 64857pr@reply-direct.com ADVERTORIAL Automation-ready tools for PCR purifi cation workfl ows


Integra Biosciences is helping labs streamline effi ciency and consistency in PCR purifi cation workfl ows by offering a range of automation-ready tools for use with magnetic beads and spin columns. These systems reduce hands-on time, improve reproducibility, and free up staff for higher-value tasks.


Magnetic bead-based purifi cation is gaining popularity for its automation potential. Integra’s MAG module enhances this process by automating vertical magnet movements, removing the need to manually transfer tubes and plates to traditional magnetic stands - reducing the risk of spills. The module also concentrates beads into a single, easy-to-aspirate pellet, rather than a ring, helping to ensure cleaner supernatant removal.


For complete walk-away automation, the MAG module integrates with the ASSIST PLUS pipetting robot and Integra electronic multichannel pipettes. This setup offers fully automated PCR purifi cation with minimal intervention and maximum reproducibility. Alternatively, labs can choose semi-automated solutions using VIAFLO 96 or VIAFLO 384 handheld pipettes, allowing simultaneous processing of 96 or 384 samples in high-throughput formats. These workfl ows are further supported by Integra’s high-yield MAGFLO™ PCR magnetic beads, optimised for amplicon recovery.


PIPETBOY GENIUS


Overfill protection


Labs using spin column-based protocols can also benefi t from Integra’s adaptable pipetting technology. VOYAGER adjustable tip spacing pipettes simplify buffer transfers from reservoirs to columns or silica membrane plates, eliminating the need for time-consuming single-channel work. For even greater time savings, the VIAFLO 96 and VIAFLO 384 enable parallel pipetting across full 96-well plates.


More information online: ilmt.co/PL/Mwlx 64664pr@reply-direct.com


Aliquot faster, aspirate safer, pipet smarter. Lightning-fast, one-button


The most revolutionary serological pipet controller repeat dispensing of aliquots


Brings color into your lab! integra-biosciences.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44